Literature DB >> 18489193

Use of prescription drugs in athletes.

Antti Alaranta1, Hannu Alaranta, Ilkka Helenius.   

Abstract

Although athletes are young and generally healthy, they use a variety of non-doping classified medicines to treat injuries, cure illnesses and obtain a competitive edge. Athletes and sports medicine physicians try to optimize the treatment of symptoms related to extreme training during an elite athlete's active career. According to several studies, the use of antiasthmatic medication is more frequent among elite athletes than in the general population. The type of training and the kind of sport influence the prevalence of asthma. Asthma is most common among those competing in endurance events, such as cycling, swimming, cross-country skiing and long-distance running. Recent studies show that athletes use also NSAIDs and oral antibacterials more commonly than age-matched controls, especially athletes competing in speed and power sports. Inappropriately high doses and concomitant use of several different NSAIDs has been observed. All medicines have adverse effects that may have deleterious effects on elite athletes' performance. Thus, any unnecessary medication use should be minimized in elite athletes. Inhaled beta(2)-agonists may cause tachycardia and muscle tremor, which are especially harmful in events requiring accuracy and a steady hand. In experimental animal models of acute injury, especially selective cyclo-oxygenase-2 inhibitors have been shown to be detrimental to tissue-level repair. They have been shown to impair mechanical strength return following acute injury to bone, ligament and tendon. This may have clinical implications for future injury susceptibility. However, it should be noted that the current animal studies have limited translation to the clinical setting. Adverse effects related to the CNS and gastrointestinal adverse reactions are commonly reported in connection with NSAID use also in elite athletes. In addition to the potential for adverse effects, recent studies have shown that NSAID use may negatively regulate muscle growth by inhibiting protein synthesis. Physicians and pharmacists taking care of athletes' medication need to be aware of the medicines that an athlete is taking and how those medicines interact with performance, exercise, environment and other medicines. Sport associations should repeatedly monitor not only the use of banned substances, but also the trends of use of legal medicines in athletes. Not only physicians and pharmacists, but also athletes and coaches should be better educated with respect to potential benefits and risks, and how each agent may affect an athlete's performance. The attitudes and beliefs leading to ample use of legal medicines in athletes is an interesting area of future research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489193     DOI: 10.2165/00007256-200838060-00002

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  129 in total

1.  Sports medicine update.

Authors:  B Berglund
Journal:  Scand J Med Sci Sports       Date:  2001-12       Impact factor: 4.221

2.  How long does the protective effect on eccentric exercise-induced muscle damage last?

Authors:  K Nosaka; K Sakamoto; M Newton; P Sacco
Journal:  Med Sci Sports Exerc       Date:  2001-09       Impact factor: 5.411

3.  Self-reported attitudes of elite athletes towards doping: differences between type of sport.

Authors:  A Alaranta; H Alaranta; J Holmila; P Palmu; K Pietilä; I Helenius
Journal:  Int J Sports Med       Date:  2006-02-01       Impact factor: 3.118

4.  The use of dietary supplements and medications by Canadian athletes at the Atlanta and Sydney Olympic Games.

Authors:  Shih-Han Susan Huang; Karin Johnson; Andrew L Pipe
Journal:  Clin J Sport Med       Date:  2006-01       Impact factor: 3.638

Review 5.  Pharmacologic treatment of exercise-induced asthma.

Authors:  B W Smith; M LaBotz
Journal:  Clin Sports Med       Date:  1998-04       Impact factor: 2.182

6.  Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors.

Authors:  I J Helenius; H O Tikkanen; S Sarna; T Haahtela
Journal:  J Allergy Clin Immunol       Date:  1998-05       Impact factor: 10.793

7.  Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses.

Authors:  Raul E Melo; Dirceu Solé; Charles K Naspitz
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

8.  Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes.

Authors:  M Sue-Chu; M Sandsund; B Holand; L Bjermer
Journal:  Int J Sports Med       Date:  2000-08       Impact factor: 3.118

9.  Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis.

Authors:  T A Trappe; F White; C P Lambert; D Cesar; M Hellerstein; W J Evans
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

Review 10.  Exercise-induced asthma, anaphylaxis, and urticaria.

Authors:  R H Kobayashi; M B Mellion
Journal:  Prim Care       Date:  1991-12       Impact factor: 2.907

View more
  24 in total

1.  Injury, pain, and prescription opioid use among former National Football League (NFL) players.

Authors:  Linda B Cottler; Arbi Ben Abdallah; Simone M Cummings; John Barr; Rayna Banks; Ronnie Forchheimer
Journal:  Drug Alcohol Depend       Date:  2011-01-28       Impact factor: 4.492

2.  Knowledge and Perceptions of Pharmacy Students in Qatar on Anti-Doping in Sports and on Sports Pharmacy in Undergraduate Curricula.

Authors:  Ahmed Awaisu; David Mottram; Alaa Rahhal; Bayan Alemrayat; Afif Ahmed; Mark Stuart; Sherief Khalifa
Journal:  Am J Pharm Educ       Date:  2015-10-25       Impact factor: 2.047

3.  Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise.

Authors:  U R Mikkelsen; H Langberg; I C Helmark; D Skovgaard; L L Andersen; M Kjaer; A L Mackey
Journal:  J Appl Physiol (1985)       Date:  2009-08-27

Review 4.  Endurance Performance is Influenced by Perceptions of Pain and Temperature: Theory, Applications and Safety Considerations.

Authors:  Christopher John Stevens; Alexis R Mauger; Peter Hassmèn; Lee Taylor
Journal:  Sports Med       Date:  2018-03       Impact factor: 11.136

5.  Nonsteroidal anti-inflammatory drug use and endurance during running in male long-distance runners.

Authors:  Eduardo Da Silva; Ronei S Pinto; Eduardo L Cadore; Luiz F Kruel
Journal:  J Athl Train       Date:  2015-01-26       Impact factor: 2.860

6.  Ibuprofen before Exercise Does Not Prevent Cortical Bone Adaptations to Training.

Authors:  Vanessa D Sherk; R Dana Carpenter; Erin D Giles; Janine A Higgins; Robera M Oljira; Ginger C Johnson; Samuel Mills; Paul S Maclean
Journal:  Med Sci Sports Exerc       Date:  2017-05       Impact factor: 5.411

Review 7.  Factors Influencing Clinical Correlates of Chronic Traumatic Encephalopathy (CTE): a Review.

Authors:  Breton M Asken; Molly J Sullan; Aliyah R Snyder; Zachary M Houck; Vaughn E Bryant; Loren P Hizel; Molly E McLaren; Duane E Dede; Michael S Jaffee; Steven T DeKosky; Russell M Bauer
Journal:  Neuropsychol Rev       Date:  2016-08-25       Impact factor: 7.444

8.  Potentially fatal new trend in performance enhancement: a cautionary note on nitrite.

Authors:  Andrea Petróczi; Declan P Naughton
Journal:  J Int Soc Sports Nutr       Date:  2010-06-29       Impact factor: 5.150

Review 9.  Management of Athletes With G6PD Deficiency: Does Missing an Enzyme Mean Missing More Games?

Authors:  Shane N Stone; Karl V Reisig; Heather L Saffel; Christopher M Miles
Journal:  Sports Health       Date:  2019-10-11       Impact factor: 3.843

10.  Recommendations of the national football league physician society task force on the use of toradol(®) ketorolac in the national football league.

Authors:  Matthew Matava; D Craig Brater; Nancy Gritter; Robert Heyer; Douglas Rollins; Theodore Schlegel; Robert Toto; Anthony Yates
Journal:  Sports Health       Date:  2012-09       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.